01
Cash & equivalents decreased 81.5%
Cash & equivalents changed -81.5% from the comparable as-filed period.
$39.5M→$7.3MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTJasper Therapeutics, Inc.'s latest supported as-filed period reports net income of -$2.8M, 89.7% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -81.5% from the comparable as-filed period.
Net income changed +89.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating income changed +66.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
JSPR · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-090055SEC ↗10-QAug 14, 2026Period Jun 30, 20260001213900-26-089592SEC ↗4Aug 4, 2026Period Jul 31, 20260001213900-26-085192SEC ↗4Aug 4, 2026Period Jul 31, 20260001213900-26-085191SEC ↗4Aug 4, 2026Period Jul 31, 20260001213900-26-085190SEC ↗4Aug 4, 2026Period Jul 31, 20260001213900-26-085189SEC ↗4Aug 4, 2026Period Jul 31, 20260001213900-26-085188SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 31, 2026Filed Aug 4, 2026 | WIGGANS THOMAS GDirector | Grant Or AwardDirect | 7,500 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -75.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-084687